Geode Capital Management
CTMX icon

Geode Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Geode Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5M Buy
4,678,716
+2,612,104
+126% +$9.97M ﹤0.01% 2228
2026
Q1 		$9.72M Buy
2,066,612
+540,946
+35% +$2.75M ﹤0.01% 2396
2025
Q4 		$6.5M Sell
1,525,666
-43,632
-3% -$166K ﹤0.01% 2628
2025
Q3 		$5.01M Sell
1,569,298
-175,878
-10% -$396K ﹤0.01% 2776
2025
Q2 		$3.96M Buy
1,745,176
+887,218
+103% +$1.43M ﹤0.01% 2851
2025
Q1 		$546K Buy
857,958
+42,315
+5% +$32.8K ﹤0.01% 3508
2024
Q4 		$840K Buy
815,643
+12,112
+2% +$13K ﹤0.01% 3428
2024
Q3 		$948K Buy
803,531
+34,032
+4% +$43.2K ﹤0.01% 3370
2024
Q2 		$939K Buy
769,499
+16,101
+2% +$32K ﹤0.01% 3330
2024
Q1 		$1.64M Buy
753,398
+50,744
+7% +$93.7K ﹤0.01% 3190
2023
Q4 		$1.09M Buy
702,654
+26,311
+4% +$34.6K ﹤0.01% 3327
2023
Q3 		$873K Buy
676,343
+32,256
+5% +$50.8K ﹤0.01% 3382
2023
Q2 		$1.11M Buy
644,087
+1,779
+0.3% +$2.95K ﹤0.01% 3305
2023
Q1 		$970K Buy
642,308
+39,233
+7% +$88.7K ﹤0.01% 3362
2022
Q4 		$964K Buy
603,075
+15,624
+3% +$23.1K ﹤0.01% 3355
2022
Q3 		$851K Buy
587,451
+4,386
+0.8% +$6.75K ﹤0.01% 3476
2022
Q2 		$1.07M Sell
583,065
-467,083
-44% -$894K ﹤0.01% 3393
2022
Q1 		$2.8M Sell
1,050,148
-123,699
-11% -$475K ﹤0.01% 3078
2021
Q4 		$5.08M Buy
1,173,847
+50,764
+5% +$297K ﹤0.01% 2894
2021
Q3 		$5.72M Sell
1,123,083
-29,927
-3% -$160K ﹤0.01% 2833
2021
Q2 		$7.3M Buy
1,153,010
+75,392
+7% +$587K ﹤0.01% 2678
2021
Q1 		$8.33M Buy
1,077,618
+319,304
+42% +$2.53M ﹤0.01% 2478
2020
Q4 		$4.97M Buy
758,314
+5,150
+0.7% +$36.8K ﹤0.01% 2608
2020
Q3 		$5.01M Buy
753,164
+44,275
+6% +$328K ﹤0.01% 2398
2020
Q2 		$5.91M Buy
708,889
+3,702
+0.5% +$34.4K ﹤0.01% 2236
2020
Q1 		$5.41M Buy
705,187
+48,930
+7% +$341K ﹤0.01% 2102
2019
Q4 		$5.45M Buy
656,257
+39,211
+6% +$265K ﹤0.01% 2397
2019
Q3 		$4.55M Buy
617,046
+18,055
+3% +$178K ﹤0.01% 2436
2019
Q2 		$6.72M Buy
598,991
+2,177
+0.4% +$22.8K ﹤0.01% 2205
2019
Q1 		$6.42M Buy
596,814
+29,913
+5% +$442K ﹤0.01% 2183
2018
Q4 		$8.56M Buy
566,901
+52,736
+10% +$782K ﹤0.01% 1878
2018
Q3 		$9.51M Buy
514,165
+151,037
+42% +$3.44M ﹤0.01% 1962
2018
Q2 		$8.3M Buy
363,128
+32,854
+10% +$839K ﹤0.01% 2022
2018
Q1 		$9.39M Sell
330,274
-17,199
-5% -$491K ﹤0.01% 1816
2017
Q4 		$7.33M Buy
347,473
+21,548
+7% +$447K ﹤0.01% 1964
2017
Q3 		$5.92M Buy
325,925
+91,162
+39% +$1.42M ﹤0.01% 2094
2017
Q2 		$3.64M Buy
234,763
+26,053
+12% +$393K ﹤0.01% 2367
2017
Q1 		$3.6M Buy
208,710
+16,991
+9% +$224K ﹤0.01% 2306
2016
Q4 		$2.11M Buy
191,719
+11,058
+6% +$134K ﹤0.01% 2597
2016
Q3 		$2.83M Buy
180,661
+104,547
+137% +$1.27M ﹤0.01% 2338
2016
Q2 		$777K Buy
76,114
+7,860
+12% +$89.6K ﹤0.01% 3016
2016
Q1 		$880 Buy
68,254
+10,184
+18% +$141K ﹤0.01% 2949
2015
Q4 		$1.21M Buy
+58,070
New +$919K ﹤0.01% 2798

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
Elmind Capital New York $398M AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's CTMX Position: Q2 2026 in Review

Geode Capital Management increased its CytomX Therapeutics (CTMX) stake by 126% in Q2 2026, buying an estimated $9.97M and bringing the position to 4,678,716 shares worth $17.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2228.

Geode Capital Management first reported a position in CTMX in Q4 2015 and has held it in 43 quarters since. 161 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Geode Capital Management held 4,678,716 shares of CytomX Therapeutics worth $17.5M as of Q2 2026.
  • Geode Capital Management bought 2,612,104 CytomX Therapeutics shares in Q2 2026, an estimated $9.97M.
  • CytomX Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2228 holding.
  • Geode Capital Management first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 43 quarters since.
  • 161 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.